What is macular degeneration?

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in adults over the age of 50. The disease affects the macula, the central portion of the retina responsible for sharp, detailed vision needed for reading, driving, recognizing faces, and performing daily activities. Although AMD usually does not cause total blindness, it can significantly impair central vision and reduce independence and quality of life if not diagnosed and treated early.

AMD develops from aging changes within the retina combined with genetic and environmental factors. Over time, retinal tissues become less efficient at clearing waste products, leading to deposits called drusen beneath the retina. Several risk factors increase the likelihood of developing AMD, including advancing age, family history, smoking, high blood pressure, high cholesterol, obesity, ultraviolet light exposure, and poor nutrition. Because early AMD can progress silently, routine eye examinations remain essential for early detection.

Common symptoms of AMD

Patients with macular degeneration may experience blurred central vision, distortion of straight lines, difficulty reading, trouble recognizing faces, dark or empty areas in central vision, reduced color sensitivity, or an increased need for brighter lighting. Symptoms may develop gradually or suddenly depending on the type of AMD involved.

There are two primary forms of AMD: wet macular degeneration and dry macular degeneration. Although both affect the same part of the retina, they behave very differently and require different treatment approaches.

Wet macular degeneration: the more serious form

Wet AMD is less common but far more aggressive and dangerous. In wet AMD, abnormal blood vessels grow beneath the retina and leak blood or fluid into the macula, causing rapid and potentially permanent vision loss if treatment is delayed. Patients may suddenly notice wavy vision, blurred central vision, distortion, or dark spots that worsen over days or weeks. Because vision can deteriorate quickly, wet AMD requires urgent evaluation and treatment.

Fortunately, major advances in retinal medicine have dramatically improved outcomes for patients with wet AMD through the use of intravitreal injections. These specialized medications are injected directly into the eye and work by reducing abnormal blood vessel growth and leakage. These treatments have revolutionized wet AMD care and have helped many patients stabilize or even improve their vision.

At Milford Franklin Eye Center, patients with wet AMD have access to advanced retinal diagnostics and modern injection therapies using the latest evidence-based treatments available today. Early diagnosis remains critical because time equals vision.

Dry macular degeneration: the most common form

Dry AMD accounts for approximately 85-90% of all cases of macular degeneration and progresses more slowly than the wet form. In dry AMD, retinal cells gradually deteriorate over time, leading to progressive central vision loss. Although it is generally less aggressive than wet AMD, dry AMD can still significantly affect quality of life and independence.

Traditionally, ophthalmologists often had difficult conversations with patients diagnosed with dry AMD because there was no direct treatment available for the disease itself. Patients were commonly told, "You have the dry form of macular degeneration. Unfortunately, there is no treatment available." While vitamins, lifestyle modifications, smoking cessation, and monitoring could sometimes slow progression, there historically has been little available to directly target the disease process.

A new breakthrough: PMB therapy for dry AMD

That is now beginning to change with the emergence of PMB therapy, one of the most exciting recent advances in ophthalmology for dry macular degeneration. PMB represents a promising new treatment option that offers hope to patients who previously had limited choices beyond observation and supportive care. This innovative technology may help slow disease progression and preserve functional vision in patients with dry AMD.

Milford Franklin Eye Center is proud to be among the first practices in Massachusetts to offer PMB therapy and currently remains the only practice in the area providing this advanced treatment option for dry AMD patients. This reflects the practice's commitment to bringing state-of-the-art retinal care and innovative technology to the community.

On-site retina specialty care

Milford Franklin Eye Center is also proud to provide on-site retina specialty care through Dr. Alyse Richard, a highly trained retina specialist dedicated to the diagnosis and treatment of retinal diseases including dry and wet macular degeneration, diabetic retinopathy, retinal vascular disease, retinal tears, and other complex retinal conditions.

Dr. Richard combines advanced subspecialty expertise with compassionate, patient-centered care and is committed to helping patients preserve their vision using the latest evidence-based treatments available today. Having on-site retina specialty care allows patients to receive comprehensive retinal evaluations, advanced imaging, injections, monitoring, and ongoing treatment in one convenient location.

Early evaluation can preserve vision

Macular degeneration remains one of the leading causes of vision loss in older adults, but advances in retinal care are rapidly transforming outcomes for patients. Early evaluation and treatment can make a meaningful difference in preserving vision, maintaining independence, and improving quality of life.

If you or a loved one has been diagnosed with dry AMD, now is the time to learn more about this exciting breakthrough in treatment. Patients are encouraged to contact Milford Franklin Eye Center for immediate appointments and second opinions regarding this revolutionary new technology that is changing the future of dry macular degeneration care.

For more details, see our ad on page 12